Stock comparison
Cintas
CTAS$67.88BIndustrials Market cap, Sector
Mycronic AB (publ)
MYCR.ST$59.4BIndustrials Market cap, Sector
Overall winner
Mycronic AB (publ)
CTAS 23 MYCR.ST
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
CTAS2wins
3winsMYCR.ST
77B
B77
84B
A85
72B
A85
69C
C69
70B
C66
80B
B78
75B
B77
Side-by-side metrics
| Metric | CTAS | MYCR.ST |
|---|---|---|
| Market cap | Winner: $67.88B | $59.4B |
| P/E (TTM) | Winner: 35.2x | 37.5x |
| EV/EBIT | 30.0x | 29.1x Winner |
| ROIC (TTM) | Winner: 23.17% | 20.79% |
| Gross margin | 50.36% | 52.44% Winner |
| Net margin | 17.57% | 19.65% Winner |
| Revenue CAGR 5y | 9.79% | 15.75% Winner |
| EPS CAGR 5y | 14.24% | 28.15% Winner |
| Debt / Equity | 0.6x | 0.0x Winner |
| Dividend yield | 1.06% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CTAS leads on
- Market cap$67.88Bvs $59.4B+12%
- ROIC (TTM)23.17%vs 20.79%+10%
- P/E (TTM)35.2xvs 37.5x+6%
MYCR.ST leads on
- Debt / Equity0.0xvs 0.6x+92%
- EPS CAGR 5y28.15%vs 14.24%+49%
- Revenue CAGR 5y15.75%vs 9.79%+38%
- Net margin19.65%vs 17.57%+11%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.